Extending the lives of women who have had extensive treatment for breast cancer that has spread is not a lost cause, conclude authors of a study published Online First in The Lancet. The study shows that monotherapy with the drug eribulin extends the lives of breast cancer patients by a median 2.5 months compared with the treatment of the physician's choice (median survival 13.1 vs 10.6 months)...
More...
Linear Mode
